多西他赛单药与长春瑞滨单药治疗老年晚期非小细胞肺癌疗效及毒性比较

目的 观察多西他赛单药和长春瑞滨单药治疗老年晚期非小细胞肺癌的疗效和毒性反应的差别.方法 选我院非小细胞肺癌患者61例,全部患者均为初治且连续使用4个周期同样方案的化疗,化疗2个周期结束后评价,除了病情进展改用其他化疗方案外,余均按原方案再巩固化疗2个周期,最后完成分组治疗病例共56例,根据采用化学治疗药物的不同分为多西他赛组(29例)和长春瑞滨组(27例).①多西他赛组:多西他赛70 mg/m2溶于0.9％氯化钠注射液250 ml,静脉滴注1h,第1,8天给药,每21天为1周期；②长春瑞滨组:长春瑞滨25mg/m2溶于0.9％氯化钠注射液100 ml,静脉滴注,1次静脉滴注时间需＞10 min,注射后0.9％氯化钠注射液冲管,第1,8天给药,每21天为1周期,观察4个周期.结果 多西他赛组完全缓解、部分缓解、稳定、进展、总有效率、1年生存率分别为3.4％ (1/29)、24.1％(7/29)、37.9％(11/29)、34.5％ (10/29)、27.6％ (8/29)和24.1％ (7/29)；长春瑞滨组相应项目分别为0、33.3％(9/27)、37.0％(10/27)、29.6％(8/27)、33.3％(9/27)和29.6％(8/27),各项指标组间差异均无统计学意义(p＞0.05).不良反应以粒细胞减少,消化道反应,口腔黏膜炎为主,组间差异均无统计学意义(P ＞0.05),2组间脱发(Ⅲ ～Ⅳ级)的差异有统计学意义(均P＜0.05).结论 单独应用多西他赛和长春瑞滨治疗老年非小细胞肺癌疗效确切并相当,老年患者的耐受性良好.

Comparison of docetaxel and navelbine in the treatment of elder-patients with advanced non-small cell lung cancer

Objective To observe the efficacy and toxic of docetaxel and navelbine in treatment of elderpatient with advanced non-small cell lung cancer. Methods Totally 56 elderly patients with advanced non-small cell lung cancer were enrolled. Twenty-nine of them were treated with docetaxel with a dose of 70 mg/m2. Twenty- seven of them were treated with navelbine 25 mg/m2. Re-evaluation was done after two cycles. Those who did not get progressed were through another two cycles of chemotherapy and all patients were followed up until disease deteriorated or patient died. Results Docetaxel group complete remission, partial remission, stable degree, progress degree,total efficiency, lyear survival rates were 3.4% （1/29） ,24.1% （7/29） ,37.9% （11/29） ,34.5% （ 10/29）, 27.6% （8/29） and 24.1% （7/29）. Navelbine group complete remission, partial remission, stable degree, progress degree, total efficiency, 1-year survival rates were 0,33.3% （9/27）, 37.0% （ 10/27 ）, 29.6% （ 8/27 ）, 33.3 % （ 9/ 27 ） and 29.6% （8/27） . There was no statistical significance between the two groups （ P 〉 0.05 ）. The common ad- verse events were neutropenia, gastrointestinal reactions and oral mucositis, and there was also no statistical significance between the two groups （P 〉 0.05 ）. But there was a statistical significance on phalacrosis （ III-IV ） between the two groups （P 〈 0.05）. Conclusions The efficacy of docetaxel and vinorelbine in the treatment of elderly nonsmall cell lung cancer are equally optimistic. Both of them are well tolerated in elderly patients.